Work

Supplemental Figure 3 from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Loss of SLFN11 confers resistance to PARP inhibition in SCLC doxcycline inducible construct against SLFN11 or Renilla luciferase with and without doxycycline exposure.

DOI: 10.1158/1078-0432.22467399

Authors: Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, Charles M. Rudin

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362402999

Cites:

Cited by:

Related to: 10